|
|
|
Oct 13, 2009 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend, our proprietary pattern recognition system, called a Downtrend for Ligand Pharmaceuticals (NASDAQ:LGND) on August 31, 2009 at $2.40. Since then, Ligand...
By Brian Orelli, Ph.D. February 5, 2009 | Comments (4) GlaxoSmithKline (NYSE: GSK) was all about cuts today -- and for good reason. Revenue was up 16% in the quarter, but that gain was entirely due to a weaker pound sterling,...
SAN DIEGO--(BUSINESS WIRE)--Jun 25, 2009 - Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today that a subsidiary of Ligand has entered into an exclusive license agreement with ParinGenix Inc. under which...
SAN DIEGO----Ligand Pharmaceuticals Incorporated announced today that a subsidiary of Ligand has entered into an exclusive license agreement with ParinGenix Inc. under which ParinGenix was granted exclusive license rights to...
